Cabaletta Bio, Inc. Gains 31.13%

Cabaletta Bio, Inc. (CABA:NASDAQ) shot up at $1.3, representing a gain of 31.1%. On Wed, Oct 19, 2022, CABA:NASDAQ hit a New 2-Week High of $1.3. The stock got featured on our News Catalysts scanner on Tue, Oct 11, 2022 at 02:35 PM in the 'MISCELLANEOUS' category. From Wed, Oct 05, 2022, the stock recorded 60.00% Up Days and 72.73% Green Days

The stock spiked on Mon, Aug 22, 2022 at $2.14 with a volume of 39M+.

About Cabaletta Bio, Inc. (CABA:NASDAQ)

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its technology uses chimeric autoantibody receptor T cells that are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies while sparing normal B cells. The firm offers preclinical development for the treatment of muscle-specific kinase myasthenia gravis, mucocutaneous PV, and Hemophilia A with factor VIII, or FVIII, alloantibodies. Its products comprise of DSG3/1-CAART, MuSK-CAART, and FVIII-CAART. The firm's initial focus is on Pemphigus Vulgaris, which is an autoimmune blistering skin disease.